| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 1 | 20 | ₹14,820 |
| HNI / NII | 14 | 280 | ₹2,07,480 |
| bHNI / bNII | 68 | 1,360 | ₹10,07,760 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 1,04,57,825 (49.98%) | — | ₹77,492.49 Cr |
| NII / HNI (Total) | — | 31,37,348 (14.99%) | — | ₹23,247.75 Cr |
| Retail Investors | — | 73,20,479 (34.98%) | — | ₹54,244.75 Cr |
| Employee | — | 10,000 (0.05%) | — | ₹7.41 Cr |
| Total ** | — | 2,09,25,652 (100.00%) | — | ₹1,550,590.82 Cr |
| Metric | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 630.75 | 736.35 | 888.48 |
| PAT | 234.89 | 174.93 | 240.08 |
| EBITDA | — | — | — |
| Net Worth | 999.37 | 1103.22 | 1290.00 |
| Total Assets | 1182.55 | 1312.80 | 1513.98 |
| Reserves | — | — | — |
| Borrowings | 86.35 | 60.59 | 31.24 |
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.
Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.
The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.
Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.